Nut Allergy Study: Double-blind Challenge and Oral Desensitization
Nut Allergy
About this trial
This is an interventional treatment trial for Nut Allergy focused on measuring Nut allergy, Double-blind placebo-controlled (DBPC) oral nut challenge, Nut oral immunotherapy (OIT), Nut oral desensitization
Eligibility Criteria
Inclusion Criteria:
- sensitization in skin prick test or in serum nut-specific IgE
- unknown anaphylaxis suspected caused by nuts
- never eaten nuts
- if challenge positive with serious symptoms, OIT
Exclusion Criteria:
- active asthma and low lung function,
- pregnancy, cardiovascular or other disease that might worsen during the challenge and OIT
Sites / Locations
- Helsinki University Central Hospital, Skin and Allergy Hospital
- Helsinki University Central Hospital, Skin and Allergy Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Placebo Comparator
Experimental
Nut challenge
Nut challenge: Placebo
Nut oral desensitization
Double-blind placebo controlled oral challenge 5-50-200-1000 mg peanut or hazelnut protein, or placebo administered with 30 min intervals and 2 hour-follow-up after the last dose.
See intervention
Patients who have moderate to severe immediate allergic reaction at peanut challenge and who enter the oral desensitization program receive peanut protein daily, from 0,1 mg to 800 mg peanut protein, maintenance dose 800 mg.